These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 16095507)

  • 1. Homocysteine-lowering therapy and early progression of transplant vasculopathy: a prospective, randomized, IVUS-based study.
    Potena L; Grigioni F; Magnani G; Ortolani P; Coccolo F; Sassi S; Kessels K; Marrozzini C; Marzocchi A; Carigi S; Musuraca AC; Russo A; Magelli C; Branzi A
    Am J Transplant; 2005 Sep; 5(9):2258-64. PubMed ID: 16095507
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interplay between methylenetetrahydrofolate reductase gene polymorphism 677C-->T and serum folate levels in determining hyperhomocysteinemia in heart transplant recipients.
    Potena L; Grigioni F; Viggiani M; Magnani G; Sorbello S; Falchetti E; Sassi S; Mantovani V; Bacchi-Reggiani L; Magelli C; Branzi A
    J Heart Lung Transplant; 2001 Dec; 20(12):1245-51. PubMed ID: 11744407
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increasing plasma homocysteine during follow-up in heart transplant recipients: effects of folate and renal function.
    Potena L; Grigioni F; Magnani G; Sorbello S; Sassi S; Marinucci L; Conti R; Carinci V; Leone O; Arpesella G; Coccheri S; Magelli C; Branzi A
    Ital Heart J; 2000 May; 1(5):344-8. PubMed ID: 10832810
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PET assessment of myocardial perfusion reserve inversely correlates with intravascular ultrasound findings in angiographically normal cardiac transplant recipients.
    Wu YW; Chen YH; Wang SS; Jui HY; Yen RF; Tzen KY; Chen MF; Lee CM
    J Nucl Med; 2010 Jun; 51(6):906-12. PubMed ID: 20484427
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Asymmetric dimethylarginine and cardiac allograft vasculopathy progression: modulation by sirolimus.
    Potena L; Fearon WF; Sydow K; Holweg C; Luikart H; Chin C; Weisshaar D; Mocarski ES; Lewis DB; Valantine HA; Cooke JP
    Transplantation; 2008 Mar; 85(6):827-33. PubMed ID: 18360263
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Folate supplementation after heart transplantation: effects on homocysteine plasma levels and allograft vascular disease.
    Potena L; Grigioni F; Magnani G; Sorbello S; Sassi S; Poci MG; Carigi S; Bacchi-Reggiani L; Leone O; Magelli C; Branzi A
    Clin Nutr; 2002 Jun; 21(3):245-8. PubMed ID: 12127934
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Timing of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor initiation and allograft vasculopathy progression and outcomes in heart transplant recipients.
    Asleh R; Briasoulis A; Pereira NL; Boilson BA; Edwards BS; Adigun R; Maltais S; Daly RC; Lerman A; Kushwaha SS
    ESC Heart Fail; 2018 Dec; 5(6):1118-1129. PubMed ID: 30019530
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Folate supplementation inhibits intimal hyperplasia induced by a high-homocysteine diet in a rat carotid endarterectomy model.
    Smith TP; Cruz CP; Brown AT; Eidt JF; Moursi MM
    J Vasc Surg; 2001 Sep; 34(3):474-81. PubMed ID: 11533600
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hyperhomocysteinemia and transplant coronary artery disease.
    Caldera A; Dec GW
    Transplantation; 2002 Nov; 74(10):1359-64. PubMed ID: 12451231
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravascular ultrasound of the proximal left anterior descending artery is sufficient to detect early cardiac allograft vasculopathy.
    Floré V; Brown AJ; Pettit SJ; West NEJ; Lewis C; Parameshwar J; Hoole SP
    Clin Transplant; 2018 Feb; 32(2):. PubMed ID: 29194769
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of hyperhomocysteinemia in hemodialysis patients and renal transplant recipients.
    Bostom AG; Shemin D; Gohh RY; Beaulieu AJ; Bagley P; Massy ZA; Jacques PF; Dworkin L; Selhub J
    Kidney Int Suppl; 2001 Feb; 78():S246-52. PubMed ID: 11169020
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High homocysteine, low folate, and low vitamin B6 concentrations: prevalent risk factors for vascular disease in heart transplant recipients.
    Gupta A; Moustapha A; Jacobsen DW; Goormastic M; Tuzcu EM; Hobbs R; Young J; James K; McCarthy P; van Lente F; Green R; Robinson K
    Transplantation; 1998 Feb; 65(4):544-50. PubMed ID: 9500631
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Everolimus Initiation and Calcineurin Inhibitor Elimination on Cardiac Allograft Vasculopathy in De Novo Heart Transplant Recipients.
    Arora S; Andreassen AK; Karason K; Gustafsson F; Eiskjær H; Bøtker HE; Rådegran G; Gude E; Ioanes D; Solbu D; Dellgren G; Ueland T; Aukrust P; Gullestad L;
    Circ Heart Fail; 2018 Sep; 11(9):e004050. PubMed ID: 30354362
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term effect of folic acid therapy in heart transplant recipients: follow-up analysis of a randomized study.
    Potena L; Grigioni F; Masetti M; Magnani G; Coccolo F; Fallani F; Russo A; Pizzuti M; Scalone A; Bianchi IG; Branzi A
    Transplantation; 2008 Apr; 85(8):1146-50. PubMed ID: 18431235
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hyperhomocysteinemia, pteridines and oxidative stress.
    Widner B; Enzinger C; Laich A; Wirleitner B; Fuchs D
    Curr Drug Metab; 2002 Apr; 3(2):225-32. PubMed ID: 12003353
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of everolimus introduction on cardiac allograft vasculopathy--results of a randomized, multicenter trial.
    Arora S; Ueland T; Wennerblom B; Sigurdadottir V; Eiskjær H; Bøtker HE; Ekmehag B; Jansson K; Mortensen SA; Saunamaki K; Simonsen S; Gude E; Bendz B; Solbu D; Aukrust P; Gullestad L
    Transplantation; 2011 Jul; 92(2):235-43. PubMed ID: 21677600
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravascular ultrasound for assessment of coronary allograft vasculopathy.
    König A; Theisen K; Klauss V
    Z Kardiol; 2000; 89 Suppl 9():IX/45-9. PubMed ID: 11151792
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of traditional cardiovascular risk factors in the recipient on the development of cardiac allograft vasculopathy after heart transplantation.
    Sánchez Lázaro IJ; Almenar Bonet L; Moro López J; Sánchez Lacuesta E; Martínez-Dolz L; Agüero Ramón-Llín J; Andrés Lalaguna L; Cano Pérez O; Ortiz Martínez V; Buendía Fuentes F; Salvador Sanz A
    Transplant Proc; 2008 Nov; 40(9):3056-7. PubMed ID: 19010192
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Follow-up study on the utility of von Willebrand factor levels in the diagnosis of cardiac allograft vasculopathy.
    Martínez-Dolz L; Almenar L; Reganon E; Vila V; Chamorro C; Andrés L; Martínez-Sales V; Moro J; Agüero J; Sánchez-Lázaro I; Salvador A
    J Heart Lung Transplant; 2008 Jul; 27(7):760-6. PubMed ID: 18582806
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term efficacy of everolimus as de novo immunosuppressant on the cardiac allograft vasculopathy in heart transplant recipients.
    Choi HI; Kang DY; Kim MS; Lee SE; Ahn JM; Lee JY; Kim YH; Park DW; Jung SH; Kim JJ
    Atherosclerosis; 2022 Sep; 357():1-8. PubMed ID: 35981436
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.